BRISTOL DISCONTINUES ORAL d-SOTALOL SWORD TRIAL
BRISTOL DISCONTINUES ORAL d-SOTALOL SWORD TRIAL on Nov. 1 because of increased mortality compared to placebo in patients taking the investigational class III (potassium channel blocking) anti-arrhythmic drug. The SWORD (Survival with Oral d-Sotalol) Data Safety Monitoring Committee examined interim data from 2,762 patients and determined that "the overall mortality in the d- sotalol group was 3.9% compared to 2% in the placebo group;" Bristol-Myers Squibb reported Nov. 4.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth